

52. The method of claim 51, wherein the composition further comprises a non-specific immune response enhancer.

53. The method of claim 52, wherein the non-specific immune response enhancer is an adjuvant.

54. The method of claim 51, wherein the subject is a human.


55. A vaccine comprising a polypeptide of claim 37 or a fusion protein of claim 38; and a physiologically acceptable carrier.

REMARKS

Original claims 1-36 have been canceled and replaced with claims 37-55. These claims add no new matter and recite antigen TB38-1, SEQ ID NO:115 (*see, e.g.,* specification, page 40, line 22).

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300